Jupiter Neurosciences Unveils Nugevia鈩� GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia鈩� GLO, a premium "beauty-from-within" supplement targeting the $8 trillion longevity market. The product combines the company's proprietary 闯翱罢搁翱尝鈩� resveratrol delivery technology with NovaSOL庐 Astaxanthin to enhance skin health at the cellular level.
Set to launch in Fall 2025 through direct-to-consumer e-commerce platforms, GLO is positioned as a high-margin product primarily targeting women over 35. The supplement leverages 闯翱罢搁翱尝鈩�, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials. The company expects the Nugevia product line to generate significant revenue and support its clinical development programs.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato il lancio di Nugevia鈩� GLO, un integratore premium "bellezza dall'interno" rivolto al mercato della longevit脿 da 8 trilioni di dollari. Il prodotto combina la tecnologia proprietaria 闯翱罢搁翱尝鈩� per la somministrazione del resveratrolo con NovaSOL庐 Astaxanthin per migliorare la salute della pelle a livello cellulare.
Previsto per il lancio nell'autunno 2025 tramite piattaforme di e-commerce direct-to-consumer, GLO 猫 posizionato come un prodotto ad alto margine rivolto principalmente a donne oltre i 35 anni. L'integratore sfrutta 闯翱罢搁翱尝鈩�, che ha dimostrato un aumento di nove volte nella biodisponibilit脿 del resveratrolo nelle prove di Fase I. L'azienda prevede che la linea di prodotti Nugevia generer脿 ricavi significativi e sosterr脿 i suoi programmi di sviluppo clinico.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado el lanzamiento de Nugevia鈩� GLO, un suplemento premium de "belleza desde el interior" dirigido al mercado de longevidad de 8 billones de d贸lares. El producto combina la tecnolog铆a patentada de entrega de resveratrol 闯翱罢搁翱尝鈩� con NovaSOL庐 Astaxanthin para mejorar la salud de la piel a nivel celular.
Con lanzamiento previsto para el oto帽o de 2025 a trav茅s de plataformas de comercio electr贸nico directas al consumidor, GLO se posiciona como un producto de alto margen dirigido principalmente a mujeres mayores de 35 a帽os. El suplemento aprovecha 闯翱罢搁翱尝鈩�, que mostr贸 un aumento de nueve veces en la biodisponibilidad del resveratrol en ensayos de Fase I. La compa帽铆a espera que la l铆nea de productos Nugevia genere ingresos significativos y apoye sus programas de desarrollo cl铆nico.
Jupiter Neurosciences (NASDAQ: JUNS)電� 8臁� 雼煬 攴滊鞚� 鞛レ垬 鞁滌灔鞚� 瓴儱頃� 頂勲Μ氙胳梽 "雮措┐鞚� 鞎勲雼れ泙" 氤挫订鞝� Nugevia鈩� GLO鞚� 於滌嫓毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞝滍拡鞚� 須岇偓鞚� 霃呾瀽鞝侅澑 闯翱罢搁翱尝鈩� 霠堨姢氩犽澕韸鸽· 鞝勲嫭 旮办垹瓿� NovaSOL庐 鞎勳姢韮�鞛旐嫶鞚� 瓴绊暕頃橃棳 靹疙彫 靾橃鞐愳劀 頂茧秬 瓯搓皶鞚� 頄レ儊鞁滍偟雼堧嫟.
2025雲� 臧�鞚�鞐� 歆侅爲 靻岆箘鞛� 雽�靸� 鞝勳瀽靸侁卑霝� 頂岆灚韽检潉 韱淀暣 於滌嫓霅� 鞓堨爼鞚� GLO電� 欤茧 35靹� 鞚挫儊鞚� 鞐劚鞚� 欤检殧 韮�旯冹溂搿� 頃橂姅 瓿犽歆� 鞝滍拡鞙茧 鞛愲Μ毵り箑頃橁碃 鞛堨姷雼堧嫟. 鞚� 氤挫订鞝滊姅 1靸� 鞁滍棙鞐愳劀 霠堨姢氩犽澕韸鸽· 靸濎泊鞚挫毄毳犾澊 9氚� 歃濌皜頃� 瓴冹溂搿� 雮橅儉雮� 闯翱罢搁翱尝鈩㈧潉 頇滌毄頃╇媹雼�. 須岇偓電� Nugevia 鞝滍拡 霛检澑鞚� 靸侂嫻頃� 靾橃澋鞚� 彀届稖頃橁碃 鞛勳儊 臧滊皽 頂勲攴鸽灗鞚� 歆�鞗愴暊 瓴冹溂搿� 旮半寑頃橁碃 鞛堨姷雼堧嫟.
Jupiter Neurosciences (NASDAQ: JUNS) a annonc茅 le lancement de Nugevia鈩� GLO, un compl茅ment premium "beaut茅 de l'int茅rieur" ciblant le march茅 de la long茅vit茅 estim茅 脿 8 000 milliards de dollars. Le produit combine la technologie propri茅taire de d茅livrance du resv茅ratrol 闯翱罢搁翱尝鈩� avec NovaSOL庐 Astaxanthin pour am茅liorer la sant茅 de la peau au niveau cellulaire.
Pr茅vu pour un lancement 脿 l'automne 2025 via des plateformes e-commerce directes aux consommateurs, GLO se positionne comme un produit 脿 forte marge ciblant principalement les femmes de plus de 35 ans. Le compl茅ment utilise 闯翱罢搁翱尝鈩�, qui a d茅montr茅 une augmentation par neuf de la biodisponibilit茅 du resv茅ratrol lors des essais de phase I. La soci茅t茅 s'attend 脿 ce que la gamme Nugevia g茅n猫re des revenus significatifs et soutienne ses programmes de d茅veloppement clinique.
Jupiter Neurosciences (NASDAQ: JUNS) hat die Markteinf眉hrung von Nugevia鈩� GLO angek眉ndigt, einem hochwertigen "Sch枚nheit von innen"-Supplement, das den 8-Billionen-Dollar-Langlebigkeitsmarkt anspricht. Das Produkt kombiniert die firmeneigene 闯翱罢搁翱尝鈩�-Resveratrol-Transporttechnologie mit NovaSOL庐 Astaxanthin, um die Hautgesundheit auf zellul盲rer Ebene zu verbessern.
Der Launch ist f眉r Herbst 2025 眉ber Direktvertriebs-E-Commerce-Plattformen geplant. GLO wird als margenstarkes Produkt positioniert, das haupts盲chlich Frauen 眉ber 35 anspricht. Das Supplement nutzt 闯翱罢搁翱尝鈩�, das in Phase-I-Studien eine neunfach erh枚hte Resveratrol-Bioverf眉gbarkeit zeigte. Das Unternehmen erwartet, dass die Nugevia-Produktlinie signifikante Ums盲tze generiert und seine klinischen Entwicklungsprogramme unterst眉tzt.
- None.
- Product launch not until Fall 2025
- Entering highly competitive beauty supplement market
- Revenue impact and market acceptance yet to be proven
Insights
Jupiter Neurosciences expands into beauty supplements with Nugevia GLO, creating new revenue stream while leveraging existing pharmaceutical technology.
Jupiter Neurosciences is strategically diversifying its business model by launching Nugevia GLO, a premium skin health supplement that leverages its proprietary JOTROL technology. This marks a significant business pivot as the company expands beyond its pharmaceutical focus into the consumer wellness market, specifically targeting the lucrative "beauty-from-within" segment of the
The company is intelligently cross-utilizing its clinical assets. JOTROL, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is being repurposed from its CNS clinical programs into this consumer product. By combining it with NovaSOL Astaxanthin, Jupiter creates a differentiated offering with scientific credibility鈥攁 crucial competitive advantage in the crowded supplement space.
This launch represents a dual-track revenue strategy. While continuing its pharmaceutical development, Jupiter is establishing a potentially faster path to commercialization through supplements. The high-margin consumer product line (including GLO, PWR, and MND) could generate near-term cash flow to help fund clinical programs, reducing reliance on dilutive financing鈥攁 common challenge for clinical-stage biotech companies.
Targeting women over 35 seeking science-backed anti-aging solutions positions GLO in a premium market segment with sustained demand and less price sensitivity. The Fall 2025 launch timeline gives investors a clear commercialization horizon, though specific revenue projections are notably absent from the announcement. The success of this strategic diversification will depend on Jupiter's execution in a competitive consumer market that demands different capabilities than pharmaceutical development.
GLO targets the growing 鈥漛eauty-from-within鈥� market with scientifically proven cellular defense and skin vitality benefits
Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing 闯翱罢搁翱尝鈩�, a proprietary resveratrol-based platform, is pleased to unveil Nugevia鈩� GLO鈥攁 pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration.
Unmatched Science Meets a Booming Market
"With Nugevia GLO, we're taking our proprietary science to a broader audience," said Christer Ros茅n, Chairman and CEO of Jupiter Neurosciences. "GLO is not just another beauty supplement鈥攊t's a clinically grounded formulation that enhances skin vitality by working at the cellular level. We're unlocking a high-growth vertical in the
Nugevia GLO leverages the potent synergy of 闯翱罢搁翱尝鈩�, Jupiter's clinically validated resveratrol delivery technology, and NovaSOL庐 Astaxanthin, a powerful antioxidant known for its skin-enhancing properties. The product will be available via direct-to-consumer e-commerce platforms beginning Fall 2025.
闯翱罢搁翱尝鈩�, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is central to Jupiter's ongoing CNS clinical programs. When combined with Astaxanthin鈥攕hown to improve skin elasticity, hydration, and pigmentation鈥攖he resulting formulation creates a best-in-class solution for skin health and systemic rejuvenation.
High-Margin, High-Impact
The GLO product launch is part of Jupiter's strategic shift into consumer wellness as a parallel growth engine to its therapeutic portfolio. Priced as a premium supplement, GLO represents a high-margin revenue stream with broad demographic appeal, including women over 35 seeking proactive skin and aging solutions grounded in real science.
Jupiter anticipates that the Nugevia rollout, including GLO, PWR and MND, will drive significant top-line growth and serve as a self-reinforcing capital engine. Revenues from GLO and the broader Nugevia line are expected to support clinical development, reduce capital dependency, and increase long-term shareholder value.
Nugevia GLO is a two-capsule-per-day regimen designed for optimal absorption and compliance. Key benefits include:
- Enhanced collagen synthesis and UV protection
- Improved hydration and reduced pigmentation
- Protection against oxidative stress and DNA damage
- Visible skin vitality through systemic cellular support
A digital press kit, including high-resolution product imagery and key brand information, is available at .
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia鈩� product line. Both efforts are powered by 闯翱罢搁翱尝鈩�, Jupiter鈥檚 proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company鈥檚 prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson鈥檚 disease, includeing indications such as Alzheimer鈥檚 Disease, Mucopolysaccharidoses Type I, Friedreich鈥檚 Ataxia, and MELAS. More information may be found on the Company鈥檚 website聽.
About JOTROL
Resveratrol is one of the world鈥檚 most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that 闯翱罢搁翱尝鈩� achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer鈥檚 Disease trial, and Yui et al., Friedreich鈥檚 Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming 闯翱罢搁翱尝鈩� trials, were published in the Journal of Alzheimer鈥檚 Disease and AAPS Open in February 2022. JUNS is now advancing 闯翱罢搁翱尝鈩� toward a Phase IIa trial in Parkinson鈥檚 Disease.
In addition to its therapeutic applications, 闯翱罢搁翱尝鈩� serves as the foundation for Jupiter鈥檚 Nugevia鈩� consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia鈩� introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company鈥檚 current expectations, including the Company鈥檚 ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渕ay鈥� or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company鈥檚 final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company鈥檚 securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
FAQ
When will Jupiter Neurosciences (JUNS) launch Nugevia GLO?
What is the technology behind Jupiter Neurosciences' Nugevia GLO supplement?
What is the target market for JUNS's Nugevia GLO product?
How will Nugevia GLO impact Jupiter Neurosciences' business model?
What are the main benefits of Jupiter Neurosciences' Nugevia GLO supplement?
